In clinical practice, it may be futile to use an immune checkpoint inhibitor for pancreatic cancer patients who stop using an ineffective first-line chemotherapy, since this strategy does not target these recruited neutrophils; furthermore, recruited neutrophil extracellular traps could even make immune checkpoint inhibitors resistant by excluding cytotoxic CD8 T cells from tumors [45]. Here, CD8A is linked to familial pancreatic carcinoma.